Phase Forward, Lilly Extend Multi-Year Agreement

Company News Release

Phase Forward (NASDAQ: PFWD), a provider of data management solutions for clinical trials and drug safety, today announced a multi-year extension agreement with Eli Lilly and Company (NYSE: LLY).

Phase Forward, Lilly Extend Multi-Year Agreement
Lilly Continues Standardization on InForm™ Platform for Clinical Data Management
WALTHAM, Mass.--(BUSINESS WIRE <http://www.businesswire.com/> )--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year extension agreement with Eli Lilly and Company (NYSE: LLY).

Since 2001, Lilly has utilized Phase Forward’s InForm product in over 200 trials and plans to continue to use InForm for global trials across all phases, as well as mandating the use of the InForm product with its global service partners.

“We look forward to continuing to leverage Phase Forward as our clinical data management solution of choice,” said Jeffrey Kasher, PhD, vice president and chief operating officer of global clinical development, Eli Lilly and Company. “Phase Forward has been a longstanding member of Eli Lilly’s Alliance Program and has been instrumental in providing Lilly with technology solutions in order to expand our global trials.”

“As an early adopter of EDC, Lilly has been a pioneer in leveraging technology to support clinical trials,” said Bob Weiler, Phase Forward’s CEO and president. “We are proud of the role our integrated solutions and global services have been able to play in their success and are delighted that we are able to continue this highly collaborative and valued partnership.”

About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture (InFormTM), phase I clinic automation (LabPasTM), clinical data management (ClintrialTM), clinical trials signal detection (CTSDTM), strategic pharmacovigilance (Empirica SignalTM) and Signal Management, adverse event reporting (Empirica TraceTM) and applied data standards (WebSDMTM). In addition, the company provides services in the areas of application implementation, hosting and validation, data integration, business process optimization, safety data management and industry standards. Phase Forward’s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 280 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at www.phaseforward.com <http://www.phaseforward.com> .